



Ryuta Saito
Japan

Professor Ryuta Saito, M.D., Ph.D., is a Professor of Neurosurgery from the Graduate School of Medicine, Nagoya University. He has held various roles in Japanese physician & healthcare associations, including in the Japan Neurosurgical Society, Japanese Brain Tumor Society, Japanese Society of Brain Tumor Pathology, Japanese Society for Brain Tumor Surgery, as well as in international associations such as the Society for Neurooncology (SNO) & American Society of Clinical Oncology (ASCO). He also served as Chairman of the Aichi Prefecture Stroke Countermeasures Promotion Committee, Deputy Branch Director of the Aichi Prefecture Stroke Association, Deputy Director of the Nagoya University Brain & Mind Research Center, Core Member of the JCOG Brain Tumor Group, Member of the JCCG Brain Tumor Committee, Director of the Japan Brain Tumor Reference Center, & Japanese Cancer Member of Therapeutic Society Guideline Creation Committee.

Topic: EF-14 Study and Case Report

Glioblastoma multiforme (GBM) is a devastating disease with poor prognosis. Optune, a portable device that administers Tumor Treating Fields (TTFields), is the first therapy in over a decade to demonstrate a clinically and statistically significant improvement in overall survival in newly diagnosed GBM patients when added to temozolomide. As part of a NCCN Category 1 Preferred regimen in the NCCN Guidelines, Optune is an important tool in a physician's armamentarium in the management of GBM.

Optune is now available in Singapore.

In this symposium, our esteemed faculty share and discuss the published scientific and clinical data behind this unique treatment modality, as well as insights into their personal and institutional experience with Optune.